FDA Issues Draft Guidance for Industry on Electronic and Non-Electronic Submissions of Promotional Materials for Human Prescription Drugs and Biologic Products?
FDA announced the availability of the draft guidance “Providing Regulatory Submissions in Electronic and Non-Electronic Format — Promotional Labeling and Advertising Materials for Human Prescription Drugs” that explains how manufacturers, packers, and distributors (firms) that may either be the applicant or acting on behalf of the applicant should make submissions pertaining to promotional materials for human prescription drugs and biologic products (“drugs”) to the FDA. Specifically, the draft guidance explains how to submit promotional materials using module 1 of the electronic Common Technical Document (eCTD) using version 3.3 or higher of the us-regional-backbone file, and aligns with the release of Module 1 Specifications v2.3, allowing CDER to accept submissions pertaining to promotional materials.
This draft guidance includes both binding and nonbinding provisions related to the submission of promotional materials. Therefore, certain promotional material-related submissions will be required to be submitted in electronic format, beginning no earlier than 24 months after this guidance is issued in final form. The guidance also describes the various types and methods of submissions of promotional materials to the Agency that will not be required to be submitted electronically.
While FDA has yet to launch the version of module 1, which will be able to accept promotional material submissions to CDER, the Agency expects to launch in the near future. FDA estimates it will be able to receive submissions utilizing Module 1 Specifications v2.3 within the 3rd Quarter of FY 2015, and will provide 30 days advance notice to industry via the eCTD web page. FDA is also encouraging people who plan to provide submissions using the eCTD specifications to work with them closely and submit samples for validation.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance